<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="3512">
  <stage>Registered</stage>
  <submitdate>29/03/2012</submitdate>
  <approvaldate>29/03/2012</approvaldate>
  <nctid>NCT01573182</nctid>
  <trial_identification>
    <studytitle>Herpes Zoster Vaccine for Bone Marrow Transplant Donors</studytitle>
    <scientifictitle>A Phase II Clinical Trial of Vaccination of Stem Cell Donors With Zostavax to Reduce the Incidence of Herpes Zoster in Transplant Recipients - A Pilot Study</scientifictitle>
    <utrn />
    <trialacronym>VZV-Zostavax</trialacronym>
    <secondaryid>VADOVAR</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Herpes Zoster</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Other infectious diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Other interventions - Zostavax

Experimental: Donor - VZV seropositive donors 50 years and over will receive vaccination with a live attenuated herpes zoster vaccine (Zostavax) by the intramuscular (IM) route 4 to 6 weeks prior to stem cell harvesting..


Other interventions: Zostavax
VZV seropositive donors 50 years and over will receive vaccination with a live attenuated herpes zoster vaccine (Zostavax) by the IM route 4 to 6 weeks prior to stem cell harvesting.

</interventions>
    <comparator />
    <control />
    <interventioncode>Other interventions interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Percentage of transplant recipients with VZV specific T cell proliferation within the first 12 moths post-transplant. - VZV specific T cell proliferation will be assessed at 3, 6, 9 and 12 months post transplant in stem cell transplant recipients.</outcome>
      <timepoint>incidence of VZV specific T cell proliferation in the first 12 months post allogeneic stem cell transplant in recipients receiving stem cells from Zostavax vaccinated donors</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Donor VZV positivity by PCR and genotype and donor VZV specific T cell response to vaccination - Donor VZV positivity by PCR and VZV specific T cell proliferation will be assessed 4 to 6 weeks after vaccination.</outcome>
      <timepoint>4 to 6 weeks after vaccination</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Allogeneic HSCT Recipient-donor pair

          -  Donor aged 50 years and over

          -  Recipients and donors willing to be recruited as a pair to this study

          -  Recipients undergoing myeloablative or non myeloablative non T cell depleted,
             allogeneic stem cell transplants from HLA identical or 1 HLA antigen mismatched
             siblings.</inclusivecriteria>
    <inclusiveminage>50</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Lack of informed consent

          -  Inability to recruit donor and recipient as a pair

          -  Autologous transplant

          -  Contraindication to Zostavax in donor

          -  Donor aged &lt;50 years

          -  Recipient VZV immunoglobulin G (IgG) negative pre-transplantation,

          -  Donor VZV IgG negative

          -  Pregnancy of donor at randomisation

          -  Inability to follow study protocol (donor and recipient)

          -  Malignancy or immunosuppression of HSC donor

          -  Expected HSCT within 30 to 42 days</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/04/2012</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>10</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/12/2018</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW</recruitmentstate>
    <hospital>Westmead Hospital - Sydney</hospital>
    <postcode>2145 - Sydney</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>University of Sydney</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to determine whether vaccination of stem cell donors with
      Zostavax can reduce the rate of Herpes Zoster reactivations in transplant recipients.

      The clinical hypotheses is: 1) that Zostavax given to stem cell donors will induce protective
      VZV specific T cell proliferation in allogeneic stem cell transplant recipients that can be
      transferred to recipients; 2) and that donor vaccination with Zostavax is safe for transplant
      recipients as measured by viral load measurement by polymerase chain reaction assay (PCR) at
      the time of stem cell donation.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01573182</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>David Gottlieb</name>
      <address>Westmead Hospital</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>David Gottlieb</name>
      <address />
      <phone />
      <fax />
      <email>david.gottlieb@sydney.edu.au</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>